Adalsteinn Gunnlaugsson
11 – 20 of 57
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Histopathology-validated gross tumor volume delineations of intraprostatic lesions using PSMA-positron emission tomography/multiparametric magnetic resonance imaging
(
- Contribution to journal › Article
-
Mark
Stereotactic body radiotherapy as metastasis-directed therapy in oligometastatic prostate cancer: a systematic review and meta-analysis of randomized controlled trials
(
- Contribution to journal › Article
-
Mark
Register data on long-term morbidity after prostate ultra-hypofractionation in the HYPO-RT-PC trial
(
- Contribution to journal › Published meeting abstract
- 2023
-
Mark
Risk of prostate cancer death after radical radiotherapy with neoadjuvant and adjuvant therapy with bicalutamide or gonadotropin-releasing hormone agonists
(
- Contribution to journal › Article
-
Mark
Urosymphyseal fistula after pelvic radiotherapy in a tertial referral centre - a rare entity with significant comorbidity requiring multidisciplinary management
(
- Contribution to journal › Article
-
Mark
MRI-only radiotherapy from an economic perspective : Can new techniques in prostate cancer treatment be cost saving?
(
- Contribution to journal › Article
- 2022
-
Mark
A prospective phase II study of prostate-specific antigen-guided salvage radiotherapy and 68Ga-PSMA-PET for biochemical relapse after radical prostatectomy - The PROPER 1 trial
(
- Contribution to journal › Article
-
Mark
Dosimetric and Clinical Predictors for Acute and Late Gastrointestinal Toxicity Following Chemoradiotherapy of Locally Advanced Anal Cancer
(
- Contribution to journal › Article
- 2021
-
Mark
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC) : patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial
(
- Contribution to journal › Article
-
Mark
Faster and more accurate patient positioning with surface guided radiotherapy for ultra-hypofractionated prostate cancer patients
(
- Contribution to journal › Article